Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993406 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
A Phase 3 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 13,970
- Enrollment target
NCT02993406 is a Phase 3 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 13,970 participants.
The verdict
NCT02993406, a Phase 3 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13,970 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.
Interventions
- DRUG Bempedoic acid 180 mg tablet
- DRUG Matching placebo tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,970 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2022-11-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02993406
The ClinicalTrials.gov registry entry for NCT02993406 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 13,970 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bempedoic acid 180 mg tablet is the first listed.
NCT02993406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02993406 about?
NCT02993406 is a clinical study titled "Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo". The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.
What is the current status of trial NCT02993406?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13,970 participants. The study started on 2016-12-22. Estimated completion is 2022-11-07.
What interventions are being tested in trial NCT02993406?
The interventions under investigation include: Bempedoic acid 180 mg tablet (DRUG), Matching placebo tablet (DRUG).
Who is sponsoring clinical trial NCT02993406?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.